| Designations: | NCI-H69 [H69] | | Depositors: | AF Gazdar | | Biosafety Level: | 1 | | Shipped: | frozen | | Medium & Serum: | See Propagation | | Growth Properties: | suspension, multicell aggregates | | Organism: | Homo sapiens | | Morphology: | floating aggregates
| | Source: | Organ: lung
Disease: carcinoma; small cell lung cancer | | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | | Receptors: | insulin-like growth factor II （IGF II） | | Tumorigenic: | Yes | | Oncogene: | myc +; myb +; fes +; fms +; raf +; ras + | | DNA Profile （STR）: | CSF1PO: 10, 12
D13S317: 12
D16S539: 11
D5S818: 11, 13
D7S820: 9
THO1: 8, 9
TPOX: 10
vWA: 16, 17
Amelogenin: XY HTB-119 NCI-H69 人肺小細胞肺癌細胞 | | Cytogenetic Analysis: | modal number = 76 to 78; range = 40 to 87
This is an aneuploid human male cell line. Monosomy of many of the normal chromosomes is noted as well as bisomy in this subtetraploid cell line; however, translocations and deletions involving many of the missing chromosomes are noted, and these chromosomal rearrangements appear to be stable and generally paired. Twelve marker chromosomes were identified including: der（16）t（1;16）（q21;q23）, der（22）t（4;22）（q12;q13）, der（12）t（11;12）（q23;p12）, del（17）（p11）, der（19）t（5;19）（?q21;q13） and others. | | Isoenzymes: | AK-1, 1
ES-D, 2
G6PD, B
GLO-I, 1-2
Me-2, 1
PGM1, 2
PGM3, 1 | | Age: | 55 years adult | | Gender: | male | | Ethnicity: | Caucasian | | Comments: | This cell line is aneuploid, will form colonies in soft agar and retains small cell carcinoma morphology and ultrastructure as well as APUD cell characteristics.
The cells grow in aggregates, thus cell counts are not accurate.
The cells stain positively for cytokeratins.
The line can be adapted to grow in shaker flask or spinner flask systems.
The N-myc gene is amplified, and there is expression of the mRNA and protein.
C-myc mRNA, but not protein, is expressed at a low level.
There is expression of c-myb, v-fes, v-fms, c-raf 1, Ha-ras, Ki-ras and N-ras mRNA. | | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C HTB-119 NCI-H69 人肺小細胞肺癌細胞 | | Subculturing: | Protocol: Attached cells can be detached by shaking flask Allow aggregates to settle to the bottom of the flask, remove and discard the supernatant medium. Add fresh medium, disperse cells by gentle pipetting and dispense into new flasks. Do not break down aggregates. Subculture every 6 to 8 days.
Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 times weekly | | Preservation: | Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature | | Related Products: | Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001
recommended serum:ATCC 30-2020
derivative:ATCC CRL-11351
purified DNA:ATCC HTB-119D | | References: | 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201
22250: Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917
22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141
22465: Broers JL, et al. Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines. J. Cell Sci. 91: 91-108, 1988. PubMed: 2473086
22869: Rygaard K, et al. Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int. J. Cancer 54: 144-152, 1993. PubMed: 8386707
23036: Gazdar AF, et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40: 3502-3507, 1980. PubMed: 6108156
23037: . . Cancer Res. 40: 4556-4563, 1980.
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258
23065: Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028
23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370
24389: . . Lung Cancer 4: 155-161, 1988.
32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760
32488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241 |
|
15
